6 completed, 3 terminated, 2 unknown, 1 active not recruiting. 13 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 13 | Completed 6, Terminated 3, Unknown 2, Active not recruiting 1, Enrolling by invitation 1 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease 12 weeks Sofosbuvir 400 mg once daily, Daclatasvir 60 mg once daily, and Ribavirin 400 mg twice daily - Heptatitis C | Not applicable | Completed | Indus Hospital and Health Network | 192 | 2024-01-10 | 2026-07-14 |
| Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years Sofosbuvir/Daclatasvir - Hepatitis C,Chronic Children, Only | Not applicable | Completed | National Liver Institute, Egypt | 42 | 2023-12-18 | 2026-10-30 |
| Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia Sofosbuvir/Daclatasvir - HCV Infection | Not applicable | Active not recruiting | ANRS, Emerging Infectious Diseases | 21000 | 2023-08-07 | 2025-12-04 |
| Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan Epclusa (nucleotide HCV NS5B polymerase inhibitors). - Hepatitis C | Not applicable | Enrolling by invitation | Queen Mary University of London | 318 | 2023-06-01 | 2025-11-21 |
| Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet, Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet - Hepatitis C, Liver Inflammation | Not applicable | Terminated | Kirby Institute | 21 | 2021-02-12 | 2026-05-26 |
| Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure Sofosbuvir, Simeprevir, Daclatasvir - HCV Coinfection | Not applicable | Completed | Assiut University | 40 | 2018-01-01 | 2019-03-19 |
| Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C Sofosbuvir, Ribavirin - Hepatitis C, Chronic, Hepatitis C Virus Infection, Response to Therapy of | Not applicable | Completed | Kawin Technology Share-holding Co., Ltd. | 136 | 2016-08-05 | 2018-03-07 |
| Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model Direct Acting Antivirals - Chronic Hepatitis c | Not applicable | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 50000 | 2016-06-18 | 2019-06-14 |
| Extrahepatic Insulin Resistance in Chronic Hepatitis C Ledipasvir 90 mg/Sofosbuvir 400 mg, Ribavirin - Insulin Resistance | Not applicable | Completed | University Hospital, Geneva | 17 | 2016-03-01 | 2019-05-01 |
| Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD) Sofosbuvir/Ledipasvir FDC - Hepatitis C, Chronic Kidney Disease | Not applicable | Terminated | Massachusetts General Hospital | 14 | 2015-07-15 | 2020-01-13 |
| To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis Sofosbuvir + Ribavirin 1, Sofosbuvir + Ribavirin 2, Sofosbuvir + Ribavirin 3 - HCV Related Cirrhosis | Not applicable | Terminated | Institute of Liver and Biliary Sciences, India | 62 | 2015-06-01 | 2017-01-19 |
| Management of Decompensated HCV Cirrhotic Patients Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol), vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion - Decompensated Cirrhosis | Not applicable | Completed | Zagazig University | 80 | 2015-06-01 | 2018-12-05 |
| Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy Combination #1, Combination #2, Combination #3 - Hepatitis C, Chronic | Not applicable | Unknown | University of Wuerzburg | 30 | 2014-10-01 | 2015-06-11 |
Hepatitis C (6) · Hepatitis C, Chronic (3) · Hepatitis (1) · Insulin Resistance (1) · Renal Insufficiency, Chronic (1)
ANRS, Emerging Infectious Diseases (1) · Assiut University (1) · Indus Hospital and Health Network (1) · Institute of Liver and Biliary Sciences, India (1) · Kawin Technology Share-holding Co., Ltd. (1) · Kirby Institute (1) · Massachusetts General Hospital (1) · National Liver Institute, Egypt (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Queen Mary University of London (1) · University Hospital, Geneva (1) · University of Wuerzburg (1) · Zagazig University (1)
Egypt (2) · India (2) · Pakistan (2) · Australia (1) · Cambodia (1) · China (1) · Germany (1) · Switzerland (1) · United States (1)
Amr S Hanafy, md (1) · Ankur Jindal, DM (1) · Elizabeth Hohmann, MD (1) · Francesco Negro, MD (1) · Graham Foster, MBBS (1) · Hosam M Basiouny, MD (1) · Howyda A El-Bhwashy, MD (1) · Lai Wei, M.D. (1) · Michael R Kraus, MD, PhD (1) · Mohamed Mekky, MD (1) · Nermin M Adawy, Prof (1) · Ola A Fouad, MD (1) · Shaimaa G Hegazy, MSC (1)
PMID 10673085, PMID 11413125, PMID 12407579, PMID 12450640, PMID 12618532, PMID 12823087, PMID 15560058, PMID 15637534, PMID 16310281, PMID 17695343, PMID 19897823, PMID 23059806, PMID 23300053, PMID 23607593, PMID 23607594, PMID 24428467, PMID 26083155, PMID 26575258, PMID 27482412, PMID 28145032, PMID 29309592, PMID 29365309, PMID 29425396, PMID 29958855, PMID 30380158, PMID 30758786, PMID 30861150, PMID 31078622, PMID 31531319, PMID 32087176, PMID 34321444, PMID 36129634, PMID 39181168, PMID 40611935